MAPT and Alzheimer disease: Alzheimer's disease (AD) is a neurodegenerative disorder of the central nervous system (CNS) with an occurrence rate of approximately 10% in the older age group.1, 2The neuropathological markers for AD are amyloid beta (Aβ) plaques and tau-containing neurofibrillary tangles (NFT).3, 4, 5The AD diagnosis is made by clinical criteria together with specific markers showing neuronal injury and AD pathology.